Phase IV Reporting Improves In Year After FDA Issues Challenge To PhRMA
Executive Summary
The pharmaceutical industry appears to be doing a significantly better job in filing Phase IV study updates in a timely fashion, FDA's postmarketing database shows
You may also be interested in...
Phase IV Status Report: Fewer Open Studies, But More Overdue Reports
The pharmaceutical industry had 67% fewer drugs and biologics with open Phase IV commitments in fiscal year 2004 than the previous year, FDA's postmarketing database shows
Phase IV Status Report: Fewer Open Studies, But More Overdue Reports
The pharmaceutical industry had 67% fewer drugs and biologics with open Phase IV commitments in fiscal year 2004 than the previous year, FDA's postmarketing database shows
E-Prescribing To Improve Postmarketing Studies, CMS’ McClellan Predicts
Electronic prescribing systems can facilitate more efficient postmarketing clinical studies, CMS Administrator Mark McClellan said April 14